497 related articles for article (PubMed ID: 27820973)
21. Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia.
Wolach O; Stone RM
Clin Cancer Res; 2015 Oct; 21(19):4262-9. PubMed ID: 26283683
[TBL] [Abstract][Full Text] [Related]
22. The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL.
Rubinstein JD; Breese EH; Krupski MC; O'Brien MM; Dandoy CE; Mizukawa B; Khoury R; Norris RE; Davies SM; Phillips CL
Transplant Cell Ther; 2023 May; 29(5):311.e1-311.e7. PubMed ID: 36809824
[TBL] [Abstract][Full Text] [Related]
23. Blinatumomab for the treatment of acute lymphoblastic leukemia.
Kaplan JB; Grischenko M; Giles FJ
Invest New Drugs; 2015 Dec; 33(6):1271-9. PubMed ID: 26383529
[TBL] [Abstract][Full Text] [Related]
24. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.
Samra B; Jabbour E; Ravandi F; Kantarjian H; Short NJ
J Hematol Oncol; 2020 Jun; 13(1):70. PubMed ID: 32503572
[TBL] [Abstract][Full Text] [Related]
25. Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia.
Sikaria S; Aldoss I; Akhtari M
Immunol Lett; 2016 Apr; 172():113-23. PubMed ID: 26921100
[TBL] [Abstract][Full Text] [Related]
26. The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia.
Horvat TZ; Seddon AN; Ogunniyi A; King AC; Buie LW; Daley RJ
Ann Pharmacother; 2018 Mar; 52(3):268-276. PubMed ID: 29025266
[TBL] [Abstract][Full Text] [Related]
27. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
Buie LW; Pecoraro JJ; Horvat TZ; Daley RJ
Ann Pharmacother; 2015 Sep; 49(9):1057-67. PubMed ID: 26041811
[TBL] [Abstract][Full Text] [Related]
28. Monoclonal antibody-based therapies in the treatment of acute lymphoblastic leukemia.
Litzow MR
Am Soc Clin Oncol Educ Book; 2013; ():294-9. PubMed ID: 23714527
[TBL] [Abstract][Full Text] [Related]
29. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
Goebeler ME; Bargou R
Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
[TBL] [Abstract][Full Text] [Related]
30. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC
J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633
[TBL] [Abstract][Full Text] [Related]
31. Novel targeted therapies in acute lymphoblastic leukemia.
Portell CA; Advani AS
Leuk Lymphoma; 2014 Apr; 55(4):737-48. PubMed ID: 23841506
[TBL] [Abstract][Full Text] [Related]
32. Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib.
El Chaer F; Holtzman NG; Sausville EA; Law JY; Lee ST; Duong VH; Baer MR; Koka R; Singh ZN; Hardy NM; Emadi A
Acta Haematol; 2019; 141(2):107-110. PubMed ID: 30695783
[TBL] [Abstract][Full Text] [Related]
33. Cytogenetic guided therapy using blinatumomab and inotuzumab ozogamicin in a patient with relapse/refractory acute lymphoblastic leukemia.
Ohana Z; Serraes S; Elder C; Katusa N
J Oncol Pharm Pract; 2022 Jul; 28(5):1269-1275. PubMed ID: 35043731
[TBL] [Abstract][Full Text] [Related]
34. Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia.
Wei G; Wang J; Huang H; Zhao Y
J Hematol Oncol; 2017 Aug; 10(1):150. PubMed ID: 28821272
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in the treatment of acute lymphoblastic leukemia.
Rafei H; Kantarjian HM; Jabbour EJ
Leuk Lymphoma; 2019 Nov; 60(11):2606-2621. PubMed ID: 31092071
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia.
Shi Z; Zhu Y; Zhang J; Chen B
Hematology; 2022 Dec; 27(1):642-652. PubMed ID: 35622074
[TBL] [Abstract][Full Text] [Related]
37. Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Yurkiewicz IR; Muffly L; Liedtke M
Drug Des Devel Ther; 2018; 12():2293-2300. PubMed ID: 30087554
[TBL] [Abstract][Full Text] [Related]
38. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.
Pulte ED; Vallejo J; Przepiorka D; Nie L; Farrell AT; Goldberg KB; McKee AE; Pazdur R
Oncologist; 2018 Nov; 23(11):1366-1371. PubMed ID: 30018129
[TBL] [Abstract][Full Text] [Related]
39. Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia.
Kiyoi H; Morris JD; Oh I; Maeda Y; Minami H; Miyamoto T; Sakura T; Iida H; Tuglus CA; Chen Y; Dos Santos C; Kalabus J; Anderson A; Hata T; Nakashima Y; Kobayashi Y
Cancer Sci; 2020 Apr; 111(4):1314-1323. PubMed ID: 31971321
[TBL] [Abstract][Full Text] [Related]
40. Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
Folan SA; Rexwinkle A; Autry J; Bryan JC
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S2-5. PubMed ID: 27521320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
